Italy drugmaker Zambon ready to splash out in U.S., China push
Share:
MILAN (Reuters) - Italian drugmaker Zambon is looking to China and the U.S. to grow its respiratory and nervous system portfolio and could spend more than 100 million euros ($114 million) on the right acquisition, its chief executive said.The family-owned pharma group, famous for its mucolytic agent Fluimucil, used to treat respiratory problems, has cash enough to fund expansion plans but could contemplate a stock market listing if a big opportunity arose."It's not on the table at the moment,..